aTyr Pharma, Inc.ATYRNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +39.59% | +30.88% | +24.67% | +28.17% | +18.48% |
| Weighted Average Shares Diluted Growth | +39.59% | +30.88% | +24.67% | +28.17% | +18.48% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -28.74% | -60.10% | -69.41% | -43.09% | -49.71% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -19.75% | -14.13% | -4.16% | +16.41% | -2.75% |
| Book Value per Share Growth | -44.67% | -32.11% | -26.44% | -4.17% | -18.66% |
| Debt Growth | -12.00% | -8.04% | -8.47% | -8.92% | -9.41% |
| R&D Expense Growth | -4.13% | -11.60% | +10.10% | +49.46% | -10.93% |
| SG&A Expenses Growth | +28.42% | +12.89% | +47.49% | +44.03% | -2.26% |